Biosite Incorporated

Ixsys, Incorporated

Bruce Andrew Lee

William D Huse

Gunars E Valkirs

Michael A Palladino

Judith A Varner

Becky Mar Flores

This invention provides novel methods, reagents, and kits that are useful for detecting. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of

[object Object]

This invention provides novel methods, reagents, and kits that are useful for detecting . The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of

Assays for detection of Bacillus anthracis

The present invention includes non-RGD cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. The inventive peptides are between five to about thirty amino acids in length and include the sequence (SEQ ID NO:8), Arg-Cys-Asp-Gly-X.sub.i where X.sub.i is any amino acid, and a five-membered cyclic portion. These non-RGD peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as cancer, osteoporosis, restenosis, and angiogenic-based diseases.

Fivemer cyclic peptide inhibitors of diseases involving .alpha..sub.v

The present invention includes non-RGD, nine amino acid cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. These peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as osteoporosis, restenosis, and angiogenic-based diseases, including cancer, arthritis, and diabetic retinopathy.

Growing community of inventors

San Diego, CA, United States of America

Bruce Andrew Lee